Search research articles
Contact Us
Filters
Showing results (51-60 of 76) with videos related to
Page
of 8
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 29, 2000
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients
S Cascinu, E Bichisao, D Amadori, et al.
Anti-Cancer Drugs
|
October 1, 1995
A comparison of the antiemetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapy
A Contu, N Olmeo, S Piro, et al.
Cancer
|
March 15, 1997
A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi
L Baldini, A Guffanti, P Gobbi, et al.
Lancet (London, England)
|
March 26, 1988
Hodgkin's disease prognosis: a directly predictive equation
P G Gobbi, C Cavalli, M Federico, et al.
Recenti Progressi in Medicina
|
May 1, 1984
[Hairy cell leukemia. Clinico-pathological study of 30 cases observed 1966 to 1979]
V Silingardi, M Federico, G Bonaccorsi, et al.
Leukemia & Lymphoma
|
April 1, 1994
Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia
A Frassoldati, T Lamparelli, M Federico, et al.
Leukemia & Lymphoma
|
April 1, 1995
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL)
V Silingardi, M Federico, L Cavanna, et al.
Haematologica
|
March 7, 2000
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL)
P G Gobbi, M L Ghirardelli, P Avanzini, et al.
Hematological Oncology
|
January 1, 1990
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy
G Merlini, G A Parrinello, L Piccinini, et al.
Haematologica
|
March 21, 1998
Hodgkin's disease presenting below the diaphragm. The experience of the Gruppo Italiano Studio Linfomi (GISL)
E Iannitto, V Accurso, M Federico, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 76) with videos related to
Sort By:
Page
of 8
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 29, 2000
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients
S Cascinu, E Bichisao, D Amadori, et al.
Anti-Cancer Drugs
|
October 1, 1995
A comparison of the antiemetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapy
A Contu, N Olmeo, S Piro, et al.
Cancer
|
March 15, 1997
A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi
L Baldini, A Guffanti, P Gobbi, et al.
Lancet (London, England)
|
March 26, 1988
Hodgkin's disease prognosis: a directly predictive equation
P G Gobbi, C Cavalli, M Federico, et al.
Recenti Progressi in Medicina
|
May 1, 1984
[Hairy cell leukemia. Clinico-pathological study of 30 cases observed 1966 to 1979]
V Silingardi, M Federico, G Bonaccorsi, et al.
Leukemia & Lymphoma
|
April 1, 1994
Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia
A Frassoldati, T Lamparelli, M Federico, et al.
Leukemia & Lymphoma
|
April 1, 1995
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL)
V Silingardi, M Federico, L Cavanna, et al.
Haematologica
|
March 7, 2000
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL)
P G Gobbi, M L Ghirardelli, P Avanzini, et al.
Hematological Oncology
|
January 1, 1990
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy
G Merlini, G A Parrinello, L Piccinini, et al.
Haematologica
|
March 21, 1998
Hodgkin's disease presenting below the diaphragm. The experience of the Gruppo Italiano Studio Linfomi (GISL)
E Iannitto, V Accurso, M Federico, et al.
Page
of 8